GlassScriptPhysician profile
Indumathi Bendi
NPI 1508818147
$6,303.82
in general payments reported to CMS, 2019-2025
45 companies · $1,501 in 2025
The $1,501 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,356 · 2020: $462 · 2021: $432 · 2022: $430 · 2023: $752 · 2024: $1,370 · 2025: $1,501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,623.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,622.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $755.70 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $612.91 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $521.79 | 2019-2025 | |
| Amgen INC. | $514.41 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $340.30 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Abbvie INC. | $300.84 | 2019-2025 | Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $281.19 | 2019-2025 | Breztri, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $268.61 | 2019-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $265.31 | 2020-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $235.93 | 2022-2025 | |
| Inspire Medical Systems, INC. | $182.26 | 2024-2025 | Inspire |
| Sanofi-Aventis U.S. LLC | $162.56 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $153.11 | 2022-2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $146.74 | 2023-2025 | |
| Astellas Pharma US INC | $138.47 | 2019-2025 | Veozah |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Indumathi Bendi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.